| Name | Title | Contact Details |
|---|
Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies.
Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient`s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.